Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation/de-escalation study of ARQ 197 administered orally in
combination with gemcitabine. The study is designed to determine the safety, tolerability and
maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of ARQ 197 when administered
in combination with gemcitabine to patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)